[Outcome measures].
Inflammatory myositis are rare and heterogeneous diseases. Most clinical and therapeutic studies differ in diagnostic and inclusion criteria as well as in improvement measures. Several collaborative study groups have recently developed and validated outcome measures for both activity and damage of these diseases. The broad use of these core set measures will result in standardized clinical studies, with more reliable results that will allow comparing between individual studies.